Table 3.
Clinical data of immune checkpoint inhibitors in T-cell lymphoma.
| Trial ID (Name) | Authors | Year | Intervention(s) | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|
|
NCT01592370 (CHECKMATE-039) |
Lesokhin et al. | 2016 | Nivolumab | Ib | MF PTCL Other CTCL Other non-CTCL |
13 5 3 2 |
0% 0% 0% 0% |
15% 40% 0% 0% |
median 10 weeks |
|
NCT01592370 (CHECKMATE-039) |
Ansell et al. | 2016 | Nivolumab + Ipilimumab | Ib | T-NHL | 11 | 0% | 9% | median 2.0 months |
| - | Kwong et al. | 2017 | Pembrolizumab | R a | NKTCL | 7 | 71% | 100% | N.A. |
| - | Li et al. | 2018 | Pembrolizumab | R a | NKTCL | 7 | 29% | 57% | median 4.8 months |
| NCT03075553 | Bennani et al. | 2019 | Nivolumab | II | ALK-neg ALCL AITL PTCL Other Non-CTCL |
1 6 3 2 |
100% 17% 0% 0% |
100% 17% 33% 50% |
median 1.9 months |
| NCT02535247 | Barta et al. | 2019 | Pembrolizumab | II | PTCL FTL MF Other non-CTCL |
7 4 3 3 |
0% 50% 33% 33% |
14% 50% 33% 33% |
median 3.2 months |
|
NCT02243579 (CITN-10) |
Khodadoust et al. | 2020 | Pembrolizumab | II | MF SS |
9 15 |
0% 13% |
56% 27% |
65% at 1 year |
All disease groups are relapsed/refractory unless otherwise specified. a Retrospective case series analyses. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed.